RÉSUMÉ
The 2019 novel coronavirus, SARS-CoV-2, is a pathogen of critical significance to international public health. Knowledge of the interplay between molecular-scale virus-receptor interactions, single-cell viral replication, intracellular-scale viral transport, and emergent tissue-scale viral propagation is limited. Moreover, little is known about immune system-virus-tissue interactions and how these can result in low-level (asymptomatic) infections in some cases and acute respiratory distress syndrome (ARDS) in others, particularly with respect to presentation in different age groups or pre-existing inflammatory risk factors. Given the nonlinear interactions within and among each of these processes, multiscale simulation models can shed light on the emergent dynamics that lead to divergent outcomes, identify actionable "choke points" for pharmacologic interventions, screen potential therapies, and identify potential biomarkers that differentiate patient outcomes. Given the complexity of the problem and the acute need for an actionable model to guide therapy discovery and optimization, we introduce and iteratively refine a prototype of a multiscale model of SARS-CoV-2 dynamics in lung tissue. The first prototype model was built and shared internationally as open source code and an online interactive model in under 12 hours, and community domain expertise is driving regular refinements. In a sustained community effort, this consortium is integrating data and expertise across virology, immunology, mathematical biology, quantitative systems physiology, cloud and high performance computing, and other domains to accelerate our response to this critical threat to international health. More broadly, this effort is creating a reusable, modular framework for studying viral replication and immune response in tissues, which can also potentially be adapted to related problems in immunology and immunotherapy.
RÉSUMÉ
Rationale: Coronavirus disease (COVID-19) is a global threat to health. Its inflammatory characteristics are incompletely understood.Objectives: To define the cytokine profile of COVID-19 and to identify evidence of immunometabolic alterations in those with severe illness.Methods: Levels of IL-1ß, IL-6, IL-8, IL-10, and sTNFR1 (soluble tumor necrosis factor receptor 1) were assessed in plasma from healthy volunteers, hospitalized but stable patients with COVID-19 (COVIDstable patients), patients with COVID-19 requiring ICU admission (COVIDICU patients), and patients with severe community-acquired pneumonia requiring ICU support (CAPICU patients). Immunometabolic markers were measured in circulating neutrophils from patients with severe COVID-19. The acute phase response of AAT (alpha-1 antitrypsin) to COVID-19 was also evaluated.Measurements and Main Results: IL-1ß, IL-6, IL-8, and sTNFR1 were all increased in patients with COVID-19. COVIDICU patients could be clearly differentiated from COVIDstable patients, and demonstrated higher levels of IL-1ß, IL-6, and sTNFR1 but lower IL-10 than CAPICU patients. COVID-19 neutrophils displayed altered immunometabolism, with increased cytosolic PKM2 (pyruvate kinase M2), phosphorylated PKM2, HIF-1α (hypoxia-inducible factor-1α), and lactate. The production and sialylation of AAT increased in COVID-19, but this antiinflammatory response was overwhelmed in severe illness, with the IL-6:AAT ratio markedly higher in patients requiring ICU admission (P < 0.0001). In critically unwell patients with COVID-19, increases in IL-6:AAT predicted prolonged ICU stay and mortality, whereas improvement in IL-6:AAT was associated with clinical resolution (P < 0.0001).Conclusions: The COVID-19 cytokinemia is distinct from that of other types of pneumonia, leading to organ failure and ICU need. Neutrophils undergo immunometabolic reprogramming in severe COVID-19 illness. Cytokine ratios may predict outcomes in this population.
Sujet(s)
Réaction inflammatoire aigüe/immunologie , Protéines de transport/métabolisme , Infections à coronavirus/immunologie , Infections à coronavirus/métabolisme , Cytokines/immunologie , Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Acide lactique/métabolisme , Protéines membranaires/métabolisme , Pneumopathie virale/immunologie , Pneumopathie virale/métabolisme , Hormones thyroïdiennes/métabolisme , alpha-1-Antitrypsine/immunologie , Réaction inflammatoire aigüe/métabolisme , Adulte , Sujet âgé , Betacoronavirus , Technique de Western , COVID-19 , Études cas-témoins , Infections communautaires/immunologie , Infections communautaires/métabolisme , Infections à coronavirus/mortalité , Infections à coronavirus/physiopathologie , Maladie grave , Électrophorèse sur gel de polyacrylamide , Test ELISA , Femelle , Hospitalisation , Humains , Unités de soins intensifs , Interleukine-10/immunologie , Interleukine-1 bêta/immunologie , Interleukine-6/immunologie , Interleukine-8/immunologie , Durée du séjour , Mâle , Adulte d'âge moyen , Granulocytes neutrophiles/immunologie , Granulocytes neutrophiles/métabolisme , Pandémies , Phosphorylation , Pneumopathie infectieuse/immunologie , Pneumopathie infectieuse/métabolisme , Pneumopathie virale/mortalité , Pneumopathie virale/physiopathologie , Récepteur au facteur de nécrose tumorale de type I/immunologie , SARS-CoV-2 , Indice de gravité de la maladie , alpha-1-Antitrypsine/métabolisme ,RÉSUMÉ
BACKGROUND: The development of thrombocytopenia in sepsis is a poor prognostic indicator associated with a significantly increased mortality risk. Mechanisms underlying this phenomenon remain to be clearly elucidated. Matrix metalloproteinases (MMPs) are enzymes that regulate the turnover of the extra-cellular matrix. MMP-2 is recognised as a platelet agonist with MMP-9 proposed as an inhibitor of platelet activation. The existence of MMP-9 in platelets is a subject of debate. There is limited evidence thus far to suggest that toll-like receptor 4 (TLR-4) and platelet-leukocyte aggregate (PLA) formation may be implicated in the development of sepsis-associated thrombocytopenia. OBJECTIVES: To investigate whether MMP -2/-9, toll-like receptor 4 (TLR-4) or platelet-leukocyte aggregate (PLA) formation are implicated in a decline in platelet numbers during septic shock. METHODS: This was an observational study which recruited healthy controls, non-thrombocytopenic septic donors and thrombocytopenic septic donors. MMP-2, MMP-9 and TLR-4 platelet surface expression as well as PLA formation was examined using flow cytometry. In addition MMP-2 and MMP-9 were examined by gelatin zymography and enzyme-linked immunosorbent assay (ELISA) using a 3 compartment model (plasma, intraplatelet and platelet membrane). RESULTS: There was no difference found in MMP-2, MMP-9 or TLR-4 levels between non-thrombocytopenic and thrombocytopenic septic donors. PLA formation was increased in thrombocytopenic patients. MMP-9 was detected in platelets using flow cytometry, gelatin zymography and ELISA techniques. CONCLUSIONS: Platelet consumption into PLAs may account for the development of thrombocytopenia in septic shock. MMP-9 is found in platelets and it is upregulated during septic shock.
Sujet(s)
Plaquettes/anatomopathologie , Leucocytes/anatomopathologie , Matrix metalloproteinase 2/sang , Matrix metalloproteinase 9/sang , Choc septique/sang , Thrombopénie/sang , Récepteur de type Toll-4/sang , Plaquettes/enzymologie , Plaquettes/métabolisme , Études cas-témoins , Femelle , Humains , Leucocytes/enzymologie , Leucocytes/métabolisme , Mâle , Adulte d'âge moyen , Activation plaquettaire/physiologie , Numération des plaquettes , Choc septique/enzymologie , Choc septique/anatomopathologie , Thrombopénie/enzymologie , Thrombopénie/anatomopathologieRÉSUMÉ
Antiplatelet therapies remain an area of potential interest for the treatment of sepsis; however, studies of platelet aggregation in sepsis have yielded conflicting results. We examined platelet aggregation patterns in patients with septic shock using quartz crystal microbalance with dissipation technology, a microfluidic device capable of measuring platelet microaggregate formation under flow conditions. Platelet aggregation was increased in the washed platelet samples of septic patients. Conversely, these same platelets aggregated less than healthy controls when examined in their plasma.